Scribd
Upload
176 views2 pages

Answer The Following Question.: Section C

Option 1 involves B-Pharma entering the European market through hostile takeovers of several European companies at a cost of $100 million. However, the European plants would need modernizing, workers may resist restructuring, and workers are concerned about B-Pharma's animal testing scandal. Option 3 involves diversifying into animal drugs through a $120 million joint venture with a Japanese company. This new market is very competitive and risky for B-Pharma as they have no experience in it. The decision tree shows Option 1 has a higher predicted revenue of $101 million compared to Option 3 whose predicted outcome is unknown.

Uploaded by

Loraine
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
176 views2 pages

Answer The Following Question.: Section C

Option 1 involves B-Pharma entering the European market through hostile takeovers of several European companies at a cost of $100 million. However, the European plants would need modernizing, workers may resist restructuring, and workers are concerned about B-Pharma's animal testing scandal. Option 3 involves diversifying into animal drugs through a $120 million joint venture with a Japanese company. This new market is very competitive and risky for B-Pharma as they have no experience in it. The decision tree shows Option 1 has a higher predicted revenue of $101 million compared to Option 3 whose predicted outcome is unknown.

Uploaded by

Loraine
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

–6– SPEC/3/BUSMT/HP1/ENG/TZ0/XX

SECTION C

Answer the following question.

5. The Board of Directors at B-Pharma are now exploring the other two strategic options:

Option 1: Market development in Europe

Likely overall cost: $100 million.

To gain productive capacity and a network of distribution channels in Europe, B-Pharma could enter
this market through hostile takeover of several European companies. The businesses could be bought
cheaply.

However, to achieve synergies, some obstacles must be overcome:


• the plants available for acquisition need modernizing. As a result they could benefit from factories
latest total quality management (TQM) methods
• European workers expect empowerment and are likely to resist any attempts at restructuring
• European workers are concerned about B-Pharma’s reputation after hearing about the animal
testing scandal.

Option 3: Diversification of the product portfolio

Likely overall cost: $120 million.

Some directors think that the company could be seen as more ethical if they made products to improve
animal welfare. B-Pharma could produce a range of drugs for animals to be sold to vets. This huge
and growing market around the world is very competitive and for B-Pharma has several risks. This
market is completely new to B-Pharma so a joint venture with an experienced Japanese company has
been suggested. B-Pharma is considering a new brand name.

The two options are summarized on the decision tree below:

Probability Forecast revenue

Option 1 Successful 0.9 $220m


$100m Not successful 0.1 $30m

Predicted
Option
outcome
Successful 0.3 $800m 1 $101m
Option 3
3 ??
$120m Not successful 0.7 $40m

(This question continues on the following page)


–7– SPEC/3/BUSMT/HP1/ENG/TZ0/XX

(Question 5 continued)

Using quantitative and qualitative data from the case study and the additional stimulus
above, recommend which option 1 or 3 is best for achieving B-Pharma’s objective of
growth.

You will find it useful to calculate the predicted outcome for Option 3 in the above
decision tree. [20 marks]

You might also like